VA Sierra Pacific Network

The present study examined the temporal relationship between posttraumatic stress disorder (PTSD) and social support among 128 male veterans treated for chronic PTSD. Level of perceived interpersonal support and stressors were assessed at two time points (6 months apart) for four different potential sources of support: spouse, relatives, nonveteran friends, and veteran peers. Veteran peers provided relatively high perceived support and little interpersonal stress. Spouses were seen as both interpersonal resources and sources of interpersonal stress. More severe PTSD symptoms at Time 1 predicted greater erosion in perceived support from nonveteran friends, but not from relatives. Contrary to expectations, initial levels of perceived support and stressors did not predict the course of chronic PTSD symptoms.

OBJECTIVE: To examine the associations between stopping treatment with opioids, length of treatment, and death from overdose or suicide in the Veterans Health Administration. DESIGN: Observational evaluation. SETTING: Veterans Health Administration. PARTICIPANTS: 1 394 102 patients in the Veterans Health Administration with an outpatient prescription for an opioid analgesic from fiscal year 2013 to the end of fiscal year 2014 (1 October 2012 to 30 September 2014). MAIN OUTCOME MEASURES: A multivariable Cox non-proportional hazards regression model examined death from overdose or suicide, with the interaction of time varying opioid cessation by length of treatment (≤30, 31-90, 91-400, and >400 days) as the main covariates. Stopping treatment with opioids was measured as the time when a patient was estimated to have no prescription for opioids, up to the end of the next fiscal year (2014) or the patient's death. RESULTS: 799 668) overall, and based on length of opioid treatment was 32.0% (≤30 days), 8.7% (31-90 days), 22.7% (91-400 days), and 36.6% (>400 days). The interaction between stopping treatment with opioids and length of treatment was significant (P<0.001); stopping treatment was associated with an increased risk of death from overdose or suicide regardless of the length of treatment, with the risk increasing the longer patients were treated. Hazard ratios for patients who stopped opioid treatment (with reference values for all other covariates) were 1.67 (≤30 days), 2.80 (31-90 days), 3.95 (91-400 days), and 6.77 (>400 days). Descriptive life table data suggested that death rates for overdose or suicide increased immediately after starting or stopping treatment with opioids, with the incidence decreasing over about three to 12 months. CONCLUSIONS: Patients were at greater risk of death from overdose or suicide after stopping opioid treatment, with an increase in the risk the longer patients had been treated before stopping. Descriptive data suggested that starting treatment with opioids was also a risk period. Strategies to mitigate the risk in these periods are not currently a focus of guidelines for long term use of opioids. The associations observed cannot be assumed to be causal; the context in which opioid prescriptions were started and stopped might contribute to risk and was not investigated. Safer prescribing of opioids should take a broader view on patient safety and mitigate the risk from the patient's perspective. Factors to address are those that place patients at risk for overdose or suicide after beginning and stopping opioid treatment, especially in the first three months.

This article distills from available data descriptions of typical human symptoms in reaction to prompt total-body ionizing radiation in the dose range 0.5 to 30 Gy midline body tissue. The symptoms are correlated with dose and time over the acute postexposure period of 6 wk. The purpose is to provide a symptomatology basis for assessing early functional impairment of individuals who may be involved in civil defense, emergency medical care and various military activities in the event of a nuclear attack. The dose range is divided into eight subranges associated with important pathophysiological events. For each subrange, signs and symptoms are designated including estimates of symptom onset, severity, duration and incidence.

Little is known about how recent ISTSS practice guidelines (E. B. Foa, T. M. Keane, & M. J. Friedman, 2000) compare with prevailing PTSD treatment practices for veterans. Prior to guideline dissemination, clinicians in 6 VA medical centers were surveyed in 1999 (n = 321) and in 2001 (n = 271) regarding their use of various assessment and treatment procedures. Practices most consistent with guideline recommendations included psychoeducation, coping skills training, attention to trust issues, depression and substance use screening, and prescribing of SSRIs, anticonvulsants, and trazodone. PTSD and trauma assessment, anger management, and sleep hygiene practices were provided less consistently. Exposure therapy was rarely used. Additional research is needed on training, clinical resources, and organizational factors that may influence VA implementation of guideline recommendations.

A new approach to wide area surveillance is described that is based on the detection and analysis of changes across two or more images over time. Methods for modeling and detecting general patterns of change associated with construction and other kinds of activities that can be observed in remotely sensed imagery are presented. They include a new nonlinear prediction technique for measuring changes between images and temporal segmentation and filtering techniques for analyzing patterns of change over time. These methods are applied to the problem of detecting facility construction using Landsat Thematic Mapper imagery. Full scene results show the methods to be capable of detecting specific patterns of change with very few false alarms. Under all conditions explored, as the number of images used increases, the number of false alarms decreases dramatically without affecting the detection performance. It is argued that the processing gain that results in using more than two images justifies the increased computational complexity and storage requirements of our approach over single image object detection and conventional change detection techniques.

Abstract Rationale Obstructive sleep apnea (OSA) is a common sleep disorder for which the principal treatment option, continuous positive airway pressure, is often poorly tolerated. There is currently no approved pharmacotherapy for OSA. However, recent studies have demonstrated improvement in OSA with combined antimuscarinic and noradrenergic drugs. Objectives The aim of this study was to evaluate the efficacy and safety of AD109, a combination of the novel antimuscarinic agent aroxybutynin and the norepinephrine reuptake inhibitor atomoxetine, in the treatment of OSA. Methods Phase II randomized, double-blind, placebo-controlled, parallel-group, 4-week trial comparing AD109 2.5/75 mg, AD109 5/75 mg, atomoxetine 75 mg alone, and placebo (www.clinicaltrials.gov identifier NCT 05071612). Measurements and Main Results Of 211 randomized patients, 181 were included in the prespecified efficacy analyses. Sleep was assessed by two baseline and two treatment polysomnograms. Apnea–hypopnea index with a 4% desaturation criterion (primary outcome) was reduced from a median (IQR) of 20.5 (12.3–27.2) to 10.8 (5.6–18.5) in the AD109 2.5/75 mg arm (−47.1%), from 19.4 (13.7–26.4) to 9.5 (6.1–19.3) in the AD109 5/75 mg arm (−42.9%; both P &amp;lt; 0.0001 vs. placebo), and from 19.0 (11.8–28.8) to 11.8 (5.5–21.5) with atomoxetine alone (−38.8%; P &amp;lt; 0.01 vs. placebo). Apnea–hypopnea index with a 4% desaturation criterion decreased from 20.1 (11.9–25.9) to 16.3 (11.1–28.9) in the placebo arm. Subjectively, there was improvement in fatigue with AD109 2.5/75 mg (P &amp;lt; 0.05 vs. placebo and atomoxetine). Atomoxetine taken alone decreased total sleep time (P &amp;lt; 0.05 vs. AD109 and placebo). The most common adverse events were dry mouth, insomnia, and urinary hesitancy. Conclusions AD109 showed clinically meaningful improvement in OSA, suggesting that further development of the compound is warranted. Clinical trial registered with www.clinicaltrials.gov (NCT 05071612).

OBJECTIVE: The effect of the COVID-19 pandemic on community-based rheumatology care and the use of telehealth is unclear. We undertook this study to investigate the impact of the pandemic on rheumatology care delivery in a large community practice-based network. METHODS: Using a community practice-based rheumatologist network, we examined trends in in-person versus telehealth visits versus canceled visits in 3 time periods: pre-COVID-19, COVID-19 transition (6 weeks beginning March 23, 2020), and post-COVID-19 transition (May-August). In the transition period, we compared patients who received in-person care versus telehealth visits versus those who cancelled all visits. We used multivariable logistic regression to identify factors associated with canceled or telehealth visits. RESULTS: Pre-COVID-19, there were 7,075 visits/week among 60,002 unique rheumatology patients cared for by ~300 providers practicing in 92 offices. This number decreased substantially (24.6% reduction) during the COVID-19 transition period for in-person visits but rebounded to pre-COVID-19 levels during the post-COVID-19 transition. There were almost no telehealth visits pre-COVID-19, but telehealth increased substantially during the COVID-19 transition (41.4% of all follow-up visits) and slightly decreased during the post-COVID-19 transition (27.7% of visits). Older age, female sex, Black or Hispanic race/ethnicity, lower socioeconomic status, and rural residence were associated with a greater likelihood of canceling visits. Most factors were also associated with a lower likelihood of having telehealth versus in-office visits. Patients living further from the rheumatologists' office were more likely to use telehealth. CONCLUSION: COVID-19 led to large disruptions in rheumatology care; these disruptions were only partially offset by increases in telehealth use and disproportionately affected racial/ethnic minorities and patients with lower socioeconomic status. During the COVID-19 era, telehealth continues to be an important part of rheumatology practice, but disparities in access to care exist for some vulnerable groups.

BACKGROUND: Varenicline is a selective nicotinic receptor partial agonist used to aid in the process of smoking cessation. Research on varenicline's approval for marketing demonstrated that after 12 weeks of treatment, at least 44% of patients successfully quit smoking and, on average, 13% of individuals discontinued therapy due to an adverse drug event (ADE). Growing postmarketing data linked varenicline to an increase in neuropsychiatric symptoms. OBJECTIVE: To evaluate the safety profile, specifically psychiatric symptoms, and effectiveness of varenicline in a veteran population and to determine whether there is an association among specific baseline demographics and success rate. METHODS: The study was a retrospective review of a prospective performance measure involving veterans initiated on varenicline. Patients were contacted via telephone throughout treatment and at week 12 for effectiveness follow-up. Smoking history was obtained and medication counseling was provided. The primary endpoint was tobacco cessation between weeks 9 and 12 of therapy. Varenicline's safety profile and discontinuation rates due to ADEs were also analyzed. RESULTS: Of the 50 patients included in the study, 30% (n = 15) successfully quit smoking and 70% (n = 35) failed therapy (lack of effectiveness, n = 22; intolerability, n = 13). Prevalence of underlying mental illness in the success group (4/15; 27%) versus failure group (20/35; 57%) was statistically significant (p < 0.001). All patients who discontinued therapy due to an increase in mood and behavioral changes (n = 4) had an underlying psychiatric illness. The study results demonstrate a lower success rate and a higher incidence of discontinuation due to an ADE in our veteran population compared with premarketing data. An inverse association was shown between psychiatric disorders and success. CONCLUSIONS: Cautious treatment initiation and close monitoring of veterans initiated on varenicline are warranted. Furthermore, the results from this study demonstrate the need for prospective effectiveness trials to determine the clinical significance of the results.

PURPOSE: The process and operational elements to establish a population health program using electronic medical record data in a Veterans Health Administration region are described. SUMMARY: Pharmacists are uniquely qualified to assume important roles in population health through the use of their clinical knowledge, assisted by electronic tools that consolidate and report patient-specific data for clinical care. Veterans Integrated Services Network (VISN) 21 has developed 300 dashboards and reports to improve the quality, safety, and value of healthcare to veterans. Within a group of specialty task forces, physicians, nurses, and pharmacists assist in the design and development of evidence-based tools to leverage timely electronic health information into metrics, benchmarks, and targets to assist with goal achievement. Examples of programs designed to improve care in 3 areas were selected for further description and review of outcomes. Population health improvement using Healthcare Effectiveness Data and Information Set and hepatitis C metrics were used to describe populations that may have an indication for evidence-based care but are not receiving it. Deprescribing efforts are described, as are medication safety monitoring efforts to prevent potential adverse events known to be associated with therapy. CONCLUSION: Quality, safety, and value outcomes are the measures of success for population health programs in VISN 21. Data-rich project dashboards and reports are developed by pharmacist data analysts and implemented and used by teams of clinicians who provide continuous feedback and support to improve population health. The use of task forces, metrics, benchmarks, targets, and teams is instrumental in the successful application of these tools.

BACKGROUND: While few countries and healthcare systems are on track to meet the World Health Organization's hepatitis C virus (HCV) elimination goals, the US Veterans Health Administration (VHA) has been a leader in these efforts. We aimed to determine which implementation strategies were associated with successful national viral elimination implementation within the VHA. METHODS: We conducted a five-year, longitudinal cohort study of the VHA Hepatic Innovation Team (HIT) Collaborative between October 2015 and September 2019. Participants from 130 VHA medical centers treating HCV were sent annual electronic surveys about their use of 73 implementation strategies, organized into nine clusters as described by the Expert Recommendations for Implementing Change taxonomy. Descriptive and nonparametric analyses assessed strategy use over time, strategy attribution to the HIT, and strategy associations with site HCV treatment volume and rate of adoption, following the Theory of Diffusion of Innovations. RESULTS: Between 58 and 109 medical centers provided responses in each year, including 127 (98%) responding at least once, and 54 (42%) responding in all four implementation years. A median of 13-27 strategies were endorsed per year, and 8-36 individual strategies were significantly associated with treatment volume per year. Data warehousing, tailoring, and patient-facing strategies were most commonly endorsed. One strategy-"identify early adopters to learn from their experiences"-was significantly associated with HCV treatment volume in each year. Peak implementation year was associated with revising professional roles, providing local technical assistance, using data warehousing (i.e., dashboard population management), and identifying and preparing champions. Many of the strategies were driven by a national learning collaborative, which was instrumental in successful HCV elimination. CONCLUSIONS: VHA's tremendous success in rapidly treating nearly all Veterans with HCV can provide a roadmap for other HCV elimination initiatives.

BACKGROUND: Cirrhosis is a rapidly increasing cause of global mortality. To improve cirrhosis care, the Veterans Health Administration (VHA) developed the Hepatic Innovation Team (HIT) Collaborative to support VA Medical Centers (VAMCs) to deliver evidence-based cirrhosis care. This randomized HIT program evaluation aims to develop and assess a novel approach for choosing and applying implementation strategies to improve the quality of cirrhosis care. METHODS: Evaluation aims are to (1) empirically determine which combinations of implementation strategies are associated with successful implementation of evidence-based practices (EBPs) for Veterans with cirrhosis, (2) manualize these "data-driven" implementation strategies, and (3) assess the effectiveness of data-driven implementation strategies in increasing cirrhosis EBP uptake. Aim 1 will include an online survey of all VAMCs' use of 73 implementations strategies to improve cirrhosis care, as defined by the Expert Recommendations for Implementing Change taxonomy. Traditional statistical as well as configurational comparative methods will both be employed to determine which combinations of implementation strategies are associated with site-level adherence to EBPs for cirrhosis. In aim 2, semi-structured interviews with high-performing VAMCs will be conducted to operationalize successful implementation strategies for cirrhosis care. These data will be used to inform the creation of a step-by-step guide to tailoring and applying the implementation strategies identified in aim 1. In aim 3, this manualized implementation intervention will be assessed using a hybrid type III stepped-wedge cluster randomized design. This evaluation will be conducted in 12 VAMCs, with four VAMCs crossing from control to intervention every 6 months, in order to assess the effectiveness of using data-driven implementation strategies to improve guideline-concordant cirrhosis care. DISCUSSION: Successful completion of this innovative evaluation will establish the feasibility of using early evaluation data to inform a manualized, user-friendly implementation intervention for VAMCs with opportunities to improve care. This evaluation will provide implementation support tools that can be applied to enhance the implementation of other evidence-based practices. TRIAL REGISTRATION: This project was registered at ClinicalTrials.Gov ( NCT04178096 ) on 4/29/20.

Objective: Academic detailing (AD) is a promising intervention to address the growing morbidity and mortality associated with opioids. While AD has been shown to be effective in improving provider prescribing practices across a range of conditions, it is unclear how best to implement AD. The present study was designed to identify key lessons for implementation based on a model AD program in the Veterans Health Administration (VA). Design: Qualitative process evaluation using semistructured interviews. Setting: Seven VA health care systems in the Sierra Pacific region. Subjects: Current and former academic detailers (N = 10) and VA providers with varying exposure to AD (high, low, or no; N = 20). Methods: Semistructured interviews were audio-recorded and transcribed. We used a team-based, mixed inductive and deductive approach guided by the Consolidated Framework for Implementation Research. Results: Key lessons identified by academic detailers and providers coalesced around key themes: 1) one-on-one sessions customized to the provider's patient population are most useful; 2) leadership plays a critical role in supporting providers' participation in AD programs; 3) tracking academic detailer and provider performance is important for improving performance for both groups; 4) academic detailers play a key role in motivating provider behavior change and thus training in Motivational Interviewing is highly valuable; and 5) academic detailers noted that networking is important for sharing implementation strategies and resources. Conclusions: Identifying and incorporating these key lessons into the implementation of complex interventions like AD are critical to facilitating uptake of evidence-based interventions addressing the opioid epidemic.

PURPOSE: The establishment and outcomes of a model primary care pharmacy service system are described. SUMMARY: A primary care pharmacy practice model was established at a government health care facility in March 1996. The original objective was to establish a primary pharmacy practice model that would demonstrate improved patient outcomes and maximize the pharmacist's contributions to drug therapy. Since its inception, many improvements have been realized and supported by advanced computer and automated systems, expanded disease state management practices, and unique practitioner and administrative support. Many outcomes studies have been performed on the pharmacist-initiated and -managed clinics, leading to improved patient care and conveying the quality-conscious and cost-effective role pharmacists can play as independent practitioners in this environment. These activities demonstrate cutting-edge leadership in health-system pharmacy. Redesign has been used to improve consistent access to a medication expert and has significantly improved the quality of patient care while easing physicians' workload without increasing health care costs. CONCLUSION: A system using pharmacists as independent practitioners to promote primary care has achieved high-quality and cost-effective patient care.

BACKGROUND AND AIMS: The Veterans Health Administration (VHA) provides care for more than 80,000 veterans with cirrhosis. This longitudinal, multimethod evaluation of a cirrhosis care quality improvement program aimed to (1) identify implementation strategies associated with evidence-based, guideline-concordant cirrhosis care over time, and (2) use qualitative interviews to operationalize strategies for a manualized intervention. APPROACH AND RESULTS: VHA providers were surveyed annually about the use of 73 implementation strategies to improve cirrhosis care in fiscal years 2018 (FY18) and 2019 (FY19). Implementation strategies linked to guideline-concordant cirrhosis care were identified using bivariate statistics and comparative configurational methods. Semistructured interviews were conducted with 12 facilities in the highest quartile of cirrhosis care to specify the successful implementation strategies and their mechanisms of change. A total of 106 VHA facilities (82%) responded at least once over the 2-year period (FY18, n = 63; FY19, n = 100). Facilities reported using a median of 12 (interquartile range [IQR] 20) implementation strategies in FY18 and 10 (IQR 19) in FY19. Of the 73 strategies, 35 (48%) were positively correlated with provision of evidence-based cirrhosis care. Configurational analysis identified multiple strategy pathways directly linked to more guideline-concordant cirrhosis care. Across both methods, a subset of eight strategies was determined to be core to cirrhosis care improvement and specified using qualitative interviews. CONCLUSIONS: In a national cirrhosis care improvement initiative, a multimethod approach identified a core subset of successful implementation strategy combinations. This process of empirically identifying and specifying implementation strategies may be applicable to other implementation challenges in hepatology.

After implementing a successful hepatitis C elimination program, the Veterans Health Administration’s (VHA) Hepatic Innovation Team (HIT) Collaborative pivoted to focus on improving cirrhosis care. This national program developed teams of providers across the country and engaged them in using systems redesign methods and population health approaches to improve care. The HIT Collaborative developed an Advanced Liver Disease (ALD) Dashboard to identify Veterans with cirrhosis who were due for surveillance for hepatocellular carcinoma (HCC) and other liver care, promoted the use of an HCC Clinical Reminder in the electronic health record, and provided training and networking opportunities. This evaluation aimed to describe the VHA’s approach to improving cirrhosis care and identify the facility factors and HIT activities associated with HCC surveillance rates, using a quasi-experimental design. Across all VHA facilities, as the HIT focused on cirrhosis between 2018–2019, HCC surveillance rates increased from 46% (IQR 37–53%) to 51% (IQR 42–60%, p &lt; 0.001). The median HCC surveillance rate was 57% in facilities with high ALD Dashboard utilization compared with 45% in facilities with lower utilization (p &lt; 0.001) and 58% in facilities using the HCC Clinical Reminder compared with 47% in facilities not using this tool (p &lt; 0.001) in FY19. Increased use of the ALD Dashboard and adoption of the HCC Clinical Reminder were independently, significantly associated with HCC surveillance rates in multivariate models, controlling for other facility characteristics. In conclusion, the VHA’s HIT Collaborative is a national healthcare initiative associated with significant improvement in HCC surveillance rates.

The ASHP Foundation Pharmacy Forecast has been a valuable source of insight and guidance about our profession as it is influenced by or influences external factors in our environment. ASHP and the ASHP Research and Education Foundation (“the Foundation”) present this ninth edition of the annual Pharmacy Forecast and are pleased to disseminate the Pharmacy Forecast through AJHP, providing readers with easy access to the report. The staff of AJHP has provided substantial editorial support for this publication, and we appreciate their assistance. The Pharmacy Forecast is a vital component of ASHP’s efforts to advance pharmacy practice leadership, and the Foundation appreciates the many pharmacists and others who have contributed to the David A. Zilz Leaders for the Future fund, which provides the resources to develop the report. The Foundation is also grateful to Omnicell for their support of the Zilz fund, which has made the Pharmacy Forecast possible. The Pharmacy Forecast could not be created without the contributions of the report’s founding editor, William Zellmer; members of the Forecast 2021 Advisory Committee; Forecast Panelists (FPs) who responded to the forecast survey; and chapter authors. ASHP and the Foundation are indebted to those individuals who have helped make the 2021 edition a success. Over the past 8 years, the Pharmacy Forecast has provided insight into emerging trends and phenomena that have impacted the practice of pharmacy and the health of patients in health systems. The value of the report is determined by its value to health-system pharmacists and health-system pharmacy leaders as they use the report to inform their strategic planning efforts. The Pharmacy Forecast is not intended to be an accurate prediction of future events. Rather, the report is intended to be a provocative stimulant for the thinking, discussion, and planning that must take place in every hospital and health system in order for those organizations to succeed in their mission of caring for patients and advancing the profession of pharmacy. Some may disagree with the opinions of the FPs or the positions taken by individual chapter authors with respect to their vision of the future. That is acceptable and desirable. Also, the report reflects a consensus of the national direction and may not reflect what is likely to occur in your geographic region or state. Reflect those differing opinions in your organization’s strategic planning process and chart a course for your organization that is consistent with your beliefs, and the Pharmacy Forecast will have met its objective of encouraging planning efforts of health systems. We welcome your comments on this new 2021 edition of the Pharmacy Forecast. Suggestions for future forecasts can be sent to any of the forecast editors through the Foundation’s Pharmacy Forecast website at http://www.ashpfoundation.org/pharmacyforecast and will be considered for future editions. Joseph T. DiPiro, PharmD, FCCP, FAAAS, Dean, School of Pharmacy, Virginia Commonwealth University, Richmond, VA Address correspondence to Dr. DiPiro (jtdipiro@vcu.edu). An underlying assumption supporting the need for the Pharmacy Forecast is that many factors influencing our profession and pharmacy services are not directly under our control, yet we can take actions that enhance the likelihood of favorable outcomes within this environment. Those influencing factors may be as a specific state or national policy or regulation, or as nebulous as the trend toward globalization (or anti-globalization). Other than the COVID-19 pandemic, the influencing factors such as the prominence of “big data,” issues of personal privacy, financing and health access are not new and have emerged over time. Within that context, then, we have greatest control over the scope of our pharmacy enterprise and the workforce within that enterprise, and some control over those factors where we can advocate to the decision makers (such as health-system administrators, legislators, and government agency officials). The perspective gained from reading the 2021 Pharmacy Forecast is most effectively used within the process of strategic planning as part of environmental scanning or when identifying strengths, weaknesses, opportunities, or threats (SWOT). In addition, the recommendations provided below can be part of the institution’s strategic planning action steps. The methods used to develop the 2021 Pharmacy Forecast were similar to those used in the previous editions, drawing on concepts described in James Surowiecki’s book The Wisdom of Crowds.1 According to Surowiecki, the collective opinions of “wise crowds”—groups of diverse individuals in which each participant’s input is provided independently, drawing from their own locally informed points of view—can be more informative than the opinion of any individual participant. This process is particularly valuable when addressing phenomena that are not well suited to quantitative predictive methods. A critical requirement for successfully creating crowd-based knowledge is establishing a systematic method of combining individual beliefs into a collective opinion—the Pharmacy Forecast uses a survey of carefully selected pharmacy leaders to derive our environmental scan. The 2021 Pharmacy Forecast Advisory Committee (see membership list in the Foreword) began the development of survey by of issues and they will health-system pharmacy in the That list and through an in a of each with on which the survey of survey to the selected and to and in the Pharmacy Forecast survey Forecast Panelists selected by ASHP staff by the leaders of the ASHP were to individuals to have in health-system pharmacy and knowledge of trends and new in the The of and within the Forecast were intended to opinions from a of pharmacy The Pharmacy Forecast survey FPs to each of the in survey and the likelihood of those in the were to their on their knowledge of in their not on their of national The carefully the of the to reflect a national were to a the likelihood of those or to This we to present in this of on Pharmacy Forecast in the of the the COVID-19 pandemic, and and within our William to reflect on the our national and it could to the of the COVID-19 on selected within the Pharmacy Forecast to the of and The of the of the method is on the of the to the forecast it is to the and of the A of FPs were to the forecast were from similar to the in previous of the FPs been in practice for than years, and been in practice for than FPs described their practice as a hospital or health of FPs were from or health systems. were from with the previous FPs that their organizations diverse health or pharmacy and of their organizations a pharmacy and provided of the FPs the of pharmacy of or of pharmacy and of of FPs their as or and as described their as of as their with the previous The of FPs leaders and at and with of FPs were by with or more and of were from of than the of the Forecast similar to that in previous in the of from each region from in and the to in the In the 2021 every region by a of Forecast by Forecast by of the report provides a of the survey and perspective of the chapter and strategic the individual survey on a specific of the the of in each chapter is and when The by and on the A assumption is that the at and the will likely such as the COVID-19 and in that could the or the of can and we within health to for access to has been an it has and as our with and access The of new provides to access to in scope of practice and for of pharmacy services to in pharmacy services and in have more and use of has more and the of use to develop more and consistent of and also the of in that have access to a of and a for past Forecast editions, is by and and a scope of from pharmacy to with and The of health is of in the chapter as for the requirement are under by and state is in the chapter by James and David and the from previous of Pharmacy Forecast. The authors the as an to the we about also the of the pharmacists as leaders and the of pharmacy and in staff and to We are that the scope of the pharmacy enterprise in health has and in the past and of access to pharmacists in as well as the for from also and likely in the and of pharmacy with in the pharmacy enterprise, have been and will to be in our pharmacy and issues are by and the issues that have been for are and also the to enhance through of and of the could be impacted by a in the of pharmacy the The of the Pharmacy Forecast is on trends that will over and and not on The 2021 edition of the Pharmacy Forecast from past by of the of that have from previous The report is intended to and discussion, providing a for individuals and who to and their and for future and trends than be to those that This is the most of for strategic the process of strategic planning pharmacy staff at the Pharmacy Forecast provides guidance to in health-system strategic planning and it is that the report be by the Pharmacy it is that at or past in to this new many of the and recommendations that are or to of the Pharmacy Forecast can be on the ASHP Foundation website at Those organizations in or the use of the Pharmacy Forecast as a and use the report as part of or to pharmacy in about the future of the profession they are to as the pharmacy workforce is to leadership, the Pharmacy Forecast many issues that are well the of pharmacy and the The of the report inform the scope of that many pharmacists The Pharmacy Forecast be with health-system leaders and as a to the pharmacy and to the emerging trends will many of health systems. Dr. DiPiro on the AJHP Advisory and of and of of Pharmacy, of on of and and Address correspondence to Dr. a and the and of the health-system pharmacists must be for to of are not new to in the and the has the of the The of and from in to in with many of the in by the of to Forecast Panelists (FPs) that at of health will develop through or similar to resources a In the of the pandemic, as were with of personal and the of that helped some and to the such as those at the and the are also guidance for Forecast to the likely is it that the will by the in the geographic region where Forecast to the likely is it that the will by the in the geographic region where health substantial from and many FPs were that resources be made to for has been were provided to health with in more than in by assistance. A from a report by the and to develop a system to for to in their to more in to health that or to the leaders have been for such a system to the likelihood of and to The FPs were on the of the of with and of with and have in years, also to in the and such as to with more for and of and to to a method to the of not A the of the the of the were that to in or that some to for their A list of to to the of the source of and or of the FPs that issues such as or will the for to not to more patients with COVID-19 in the those were to an from than this to The Research and provided a to and the intended to to also to to the over a of FPs the will to from to The about on and by the most for in the are the most and of some have been to system and of access for of has been for were to for more of in the of by the of may not be may develop for to (or by the of of those of without in the made by of the and could or enhance your health for with health and and state to for or of resources such as to on when and that on of health also a of policy within your of at your health within state and national hospital and pharmacy to support that on and the of Dr. is an of the for and a of the AJHP Advisory The of has a to with The value of the than of the for also on the AJHP Advisory Dr. is by and the for FCCP, and of of Pharmacy, and of of of FCCP, and of Pharmacy and of of Pharmacy, of Pharmacy and of of Pharmacy, Address correspondence to Dr. to the health of those in of the the health of the COVID-19 and the of health in the it is to to of pharmacy and their in scope of of and access to than of Forecast Panelists (FPs) of access to in and use of to services and outcomes and in will and have the for this to In we have a in the COVID-19 pandemic, with such as are and for access to may be a in some and to be use of for services such as of and and recommendations will likely to to its and Forecast to the likely is it that the will by the in the geographic region where Forecast to the likely is it that the will by the in the geographic region where of FPs that pharmacy will be with patients and in and to access An which pharmacy with patients to and access and outcomes and of of FPs it is not likely that pharmacy will take on this with pharmacy can successfully support is pharmacy leaders to the pharmacy can as their scope of practice may and to and the patients they of FPs of will have a through which scope of practice can be when health are as in the with of pharmacists to the in to the COVID-19 pandemic, the and pharmacists to order and COVID-19 and the of state to of by and by pharmacists more the of scope of and more health is a in the of FPs were on at of health will their with the of health and health that their region from to the as they to be the of a is with of national organization and to which more in and and many the of a or will to and likely not be in the future. The of FPs not that at of health will access to likely to and as to the of and of use is under and hospital through the for and health that access to at as use could in of or substantial at of in and have from use of of by is to by may be to in health systems. The in on with which hospital into the hospital by their or 8 into the health system pharmacy and of and into the and for In addition, began in the of of control and of for and in for the on the use of the to that will enhance the outcomes of patients in your health those in pharmacy in your pharmacy enterprise can be more and effectively by to enhance and with pharmacy leaders in your state the and of any pharmacy scope of practice that in to the or health with the pharmacy leaders of health in your region the for of and the a process within your health system of to use of The authors have of VA are and for a in pharmacy health have on health and which health and that the The has to place more on the of and this knowledge through the and of that an as a the likelihood that will be used for and decision Pharmacy as by the and on and knowledge within the of its use and the of and health and health are not from pharmacy and pharmacy they not a as some have In more be on pharmacy as the and use of from to practice outcomes and within pharmacy and use to support and individual and health and with for and health will be with use that will present and may be and for within the at the be and to use of to the and of for the of and the development of that of they are The of a in each health or with health is within systems. Forecast Panelists (FPs) a the likelihood of used for of this for a pandemic, or to may be more than FPs were on health will have that of with will be by and about by be they or of FPs that over the health the of and to are to in with the and or many health health as and may not to from their with pharmacists or of the health may be to for are many to and to outcomes and may be to and the for to in FPs that will be used to for patients for This may be on the knowledge that and health to of every Pharmacy guidance on to will be are through the use of and and of FPs will be used to and to to be this will be to or to of FPs it likely that within the will when a order from the institution’s of use recommendations over of will be to to and support decision and the of their use on Forecast to the likely is it that the will by the in the geographic region where Forecast to the likely is it that the will by the in the geographic region where and a of with pharmacists to make for individual patients are to for or through that the and of and for and in the to and use that pharmacy with the health-system to and issues to patients and Pharmacy have the and to of and or issues in the process that development of an in and of that of hospital and for and outcomes the strategic direction of pharmacy and pharmacy as well as and use the of knowledge into pharmacy that and of to and health and enhance and health with the health and the of and individuals to their new pharmacy of that use guidance to in that and that outcomes and to the and of the institution’s develop and that and outcomes are for and Dr. on the AJHP Advisory Dr. has of Pharmacy Address correspondence to many of financing and by the COVID-19 and state of their to to the pandemic, in on issues and and to on issues such as to the began with the to Forecast Panelists The with has on the pharmacy leaders with as they the future. is in at the and state FPs were in that the trend of state government to by will it is that is not to or and are also under for as by the for and at the of Pharmacy leaders to with government leaders in their health by with establishing a pharmacy and for that access to and of Forecast to the likely is it that the will by the in the geographic region where Forecast to the likely is it that the will by the in the geographic region where The past have a in of for organizations and have to of critical of FPs that or more of the used by health in the future will be through This could in a more for Pharmacy leaders in of and of to the of a pharmacy for possible. The survey in this of the Forecast that the most the of health will or more for of FPs this or most health and have with with The of of is some of the with and a process to outcomes over time. The for and is to some of in its that and the could to and health in more with as health take on more under organization or similar pharmacy leaders the use of to of In the to in the of health and the of and health In the Forecast of FPs it likely that and state for health systems. The has in for health a on the of the of our The of opinion of and for health may the likelihood of state and government actions that health systems. action that will health has The of the national and are likely to have an on the likelihood that will be specific action addressing the of and health systems. in the pharmacy are to to will the of any as survey the for to the That is the for in this The is about the likelihood that external could to the of FPs were in their about the of this with it likely and it The the that of will of the of that this is at likely to occur That more than of the FPs responded to is to about the of the in the pharmacy and are more than to services through that may external with health and A of survey that this may occur with external that to The of over the past has in the pharmacy Pharmacy leaders with respect to external and the of on of the be to the value health-system pharmacy is and the of strategic planning for pharmacy of the for to some or of a health-system pharmacy can be an for and with health-system government establishing a pharmacy policy that can be used to advocate at the state and national Pharmacy leaders the health-system policy and be to trends in the and environment. Pharmacy leaders with health-system leaders to for critical be possible. a of the and of the with system leaders pharmacy leaders to that are in with the organization and the likelihood of success. every of the pharmacy enterprise with respect to value to the and the that the or be by and in the future. The authors have of David of and of and James and Research Address correspondence to Dr. has been a for which pharmacists are suited to this on the of efforts and health systems. to of for the system in health toward through new new the and many pharmacists with the most have new to through a use of the staff and Forecast Panelists responded that it or that from will or pharmacists may a of from as This with a vision of that is a in a of health Some on through to staff and the of this to in such as and through and the in and are for not have the or of the The a to to and it can new to an organization’s efforts an on (or also not and on to the of to FPs may have been in this Forecast to the likely is it that the will by the in the geographic region where Forecast to the likely is it that the will by the in the geographic region where a vision for must be with and we not this a for which is must the for from to and health-system vision must be with action and to and The of use must a and to and that will The underlying used by the and to has to use and new are and of the in has a of from The COVID-19 has to use a of new with or from Forecast survey as the COVID-19 of FPs it or likely that health pharmacy and will more the and of new of for The system a to and use a health and must on its to the for new to use the system to of and support for use The for is and FPs it likely issues be at the health-system and through in FPs it or likely that in of health the pharmacy will have an to support the and of its staff staff is to staff is not staff the staff in health some that from pharmacy efforts are from a on specific to staff support resources to many of in the from the COVID-19 pandemic, the need for resources has FPs were that in at of health a will be in an with it or likely This is consistent with the Pharmacy in which FPs it likely that pharmacy leaders take on by on and the health system to pharmacists have successfully taken on such pharmacists have the knowledge of the with as a which they can to in of in health systems. the system many and a of of a health it is for a to every of a or for a to be in an with to strategic for use and new by provocative on can be and into strategic with and a pharmacists are in health-system to and be to make contributions to the new and to and from the system to the and of used to new and or when is to be of the specific support resources in your health and specific actions for the of pharmacy members in the strategic planning Dr. on the AJHP Advisory Dr. has of A. of Pharmacy, PharmD, Pharmacy Address correspondence to Dr. DiPiro (jtdipiro@vcu.edu). The from to value in has been the pharmacy enterprise to on and of outcomes the of are toward use of for are with to in this of providing Forecast Panelists (FPs) that pharmacists will likely a in addressing the of services in and or and an for and access at the of the Forecast to the likely is it that the will by the in the geographic region where Forecast to the likely is it that the will by the in the geographic region where health have outcomes by pharmacists in to and patients and on the in is a to access of in many pharmacists practice and in access possible. The of pharmacists as part of will as the are and and for health FPs were to on the likelihood of positions to such as and health will likely to their services in and more pharmacists will practice in what will positions from in in new This will on the of in services or pharmacists of into their The on state by the of with health and to from will in of pharmacists in in workforce will be positions of to the of the pharmacy A of FPs that the pharmacy staff will An accurate and is to the and its are well in the of ASHP’s is of the vital pharmacy have in The pharmacy is to through of to their knowledge of and and access to the that are accurate and by the are critical in of of for members of the as likely or likely to occur by of FPs and of to and use of must be to is a within the hospital are for of a The to in are methods by which and recommendations can be made in the by FPs that pharmacists will for patients with with for is an for pharmacists to health The in a of services on development of a and state and and of FPs that and in health will will be critical as and are and to be in The and must that pharmacists to have the to practice in those providing with and for must be and to the develop a strategic to for pharmacy enterprise into and and where access to a can be for for pharmacists to of services patients with their in and as well as where access and to can be services to patients in the health system to that is that of pharmacists services are in the and that such is to the of services by pharmacists for patients in and in which is a for the of the in and health that pharmacists have the and to The authors have of A. for and The of of Pharmacy, and School of Pharmacy, and School of of Address correspondence Dr. Pharmacy workforce

National healthcare policy is affecting the way health systems provide care by mandating accountability through standardized performance measures and incentives for improvement. Health systems are responding by adopting management systems—in many cases, systems from other industries—to measure process and patient outcomes. Studying value streams to improve daily management systems and goal attainment is now becoming more common with increased efforts to measure and improve complex healthcare delivery systems. Many healthcare systems are focused on service improvement models to train and engage both employees and patients and to implement the changes needed to improve our healthcare system. These newly embedded “integrated practices” are designed to improve quality, safety, and value. As changes occur in healthcare, the missions and goals of healthcare systems are shifting. In fact, changes are occurring so rapidly that many systems may have difficulty articulating and achieving health-system goals effectively. However, there is no lack of suggested performance measures and metrics from many sources.

A study of the 3- μm laser transitions in Ho:YAlO3and Nd,Ho:YAlO3using both flashlamp and laser pumping is discussed. Fluorescence measurements for the Nd,Ho:YAlO3rod indicate that the neodymium is effective in quenching the lower holmium laser level and in sensitizing the upper level. Intracavity laser pumping of Ho:YAlO3produced laser lines at 2.92 and 2.85 μm and demonstrated high efficiency.

BACKGROUND: Chronic opioid therapy-clinical reminder (COT-CR) is a decision support tool to prompt providers to carefully assess patients prescribed chronic opioids. This tool was developed to address inappropriate opioid prescribing. OBJECTIVE: To determine COT-CR's impact on reducing morphine equivalent monthly dose (MEMD) and risk index for overdose or serious prescription opioid-induced respiratory depression (RIOSORD) values in veterans receiving chronic opioids. METHODS: This retrospective cohort review matched patients with a complete COT-CR to patients with an incomplete COT-CR using propensity scores. In the primary aim, an interrupted time series design evaluated for changes in MEMD 12 months before and 6 months after the index date. The index date was the first pain or primary care provider visit post COT-CR installation. In the secondary aims, a retrospective cohort design was used to evaluate the changes in RIOSORD index score and risk class 6 months after the index date. RESULTS: After matching, 3801 patients were included in the complete and incomplete COT-CR groups, respectively. Greater average reduction in MEMD (-11.6 MEMD; 95% CI = -0.97 to -22.25 MEMD; P = 0.032) and RIOSORD index score (-0.53 RIOSORD index score; 95% CI = -1.00, -0.05 RIOSORD index score; P = 0.030) was observed in patients with a complete COT-CR compared to patients with an incomplete COT-CR. Differences in RIOSORD risk class were insignificant. CONCLUSION: Completing the COT-CR was associated with reduced MEMD and RIOSORD values. This suggests that active monitoring can change prescribing patterns, thereby, reducing the overall risk of opioid overdose in at-risk veterans.

BACKGROUND: Screening for colorectal cancer (CRC) with faecal immunochemical test (FIT) is effective at reducing CRC mortality. Unfortunately, the COVID-19 pandemic has been associated with deferred care, especially screening for CRC. AIM: We sought to develop a mailed FIT programme (MFP) to increase CRC screening and make recommendations for adoption across the Veterans Health Administration (VHA) and for other large healthcare systems. SETTING: 2 regional VA medical centres in California and Washington state. PARTICIPANTS: 5667 average risk veterans aged 50-75 overdue or due within 90 days for CRC screening. PROGRAMME DESCRIPTION: A multidisciplinary implementation team collaborated to mail an FIT kit to eligible veterans. Both sites mailed a primer postcard, and one site added an automated reminder call. PROGRAMME EVALUATION: We monitored FIT return and positivity rate, as well as impact of the programme on clinical staff. 34% of FIT kits were returned within 90 days and 7.8% were abnormal. DISCUSSION: We successfully implemented a population-based MFP at multiple regional VA sites and recommend that these efforts be spread across VA. Our model of regional leadership, facility champions and using centralised resources can be adaptable to other large healthcare systems. MFPs support catch-up from disrupted care by addressing access to CRC screening, unburden primary care visits and conserve limited procedural resources.